Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

IgA Nephropathy (IgAN)IgAVN

Interventions

DRUG

Telitacicept

The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks.

All Listed Sponsors

lead

Guixia Ding

OTHER